Sugi Predict

Sugi Predict / Compounds / SCHEMBL22494449

SCHEMBL22494449

SCHEMBL22494449

CC(C)n1nc(I)c2c(Cl)nc(N)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 16/20 0.47
▸ PIK3CA P42336 12/20 0.47
▸ RICTOR Q6R327 9/20 0.47
▸ RPTOR Q8N122 9/20 0.47
▸ MAPKAP1 Q9BPZ7 9/20 0.47
▸ MLST8 Q9BVC4 9/20 0.47
▸ ADORA2A P29274 2/20 0.39
▸ ADORA1 P30542 2/20 0.39
▸ ABL1 P00519 5/20 0.33
▸ SRC P12931 5/20 0.33
▸ PIK3CD O00329 4/20 0.33
▸ EGFR P00533 4/20 0.33
▸ HCK P08631 4/20 0.33
▸ KDR P35968 4/20 0.33
▸ PIK3CB P42338 4/20 0.33
▸ EPHB4 P54760 4/20 0.33
▸ PRKDC P78527 4/20 0.33
▸ PIK3CG P48736 3/20 0.33
▸ CDK1 P06493 1/20 0.31
▸ CCNB1 P14635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31403518 0.81 MTOR (0.47) MTORPIK3CARICTORRPTORMAPKAP1
SCHEMBL25643080 0.78 ADORA2A (0.38) MTORPIK3CARICTORRPTORMAPKAP1
SCHEMBL22494314 0.77 CDK1 (0.35) MTORPIK3CARICTORRPTORMAPKAP1
SCHEMBL27217868 0.72 ABL1 (0.43) MTORPIK3CAABL1SRCPIK3CD
SCHEMBL22494322 0.69 PTK6 (0.34) MTORPIK3CARICTORRPTORMAPKAP1
SCHEMBL22494331 0.68 MTOR (0.50) MTORPIK3CARICTORRPTORMAPKAP1
SCHEMBL30381902 0.68 MTOR (0.50) MTORPIK3CARICTORRPTORMAPKAP1
SCHEMBL22494329 0.68 MTOR (0.50) MTORPIK3CARICTORRPTORMAPKAP1
SCHEMBL31403592 0.68 KDR (0.40) MTORPIK3CAABL1SRCPIK3CD
SCHEMBL14655857 0.68 PIK3CA (0.48) MTORPIK3CARICTORRPTORMAPKAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076284-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME DELPHIA THERAPEUTICS, INC. (US) 2025-04-10 — — WO disclosed
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors GALDERMA RESEARCH & DEVELOPMENT (FR) 2023-08-22 — — US disclosed
EP-3727389-B1 COMPOUNDS AS MTOR INHIBITORS GALDERMA RES & DEV (FR) 2023-05-03 — — EP disclosed
CN-111918653-A Novel MTOR inhibitor compounds 盖尔德马研究及发展公司 2020-11-10 — — CN disclosed
EP-3727389-A1 NOVEL MTOR INHIBITOR COMPOUNDS Galderma Research & Development (FR) 2020-10-28 — — EP disclosed
US-20200317679-A1 NOVEL MTOR INHIBITOR COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317679-A1 NOVEL MTOR INHIBITOR COMPOUNDS MTOR, RICTOR, RPTOR MTOR 1/4885PIK3CA 23/4885RICTOR 2/4885
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors MTOR, RICTOR, RPTOR MTOR 1/4885PIK3CA 9/4885RICTOR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.